Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma
Journal of Gastroenterology and Hepatology · 2025-10 · 40 (10) · 2580-2590
DOI: 10.1111/jgh.70068 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 09.09.2025. Verfasst von Kazuki Maesaka und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Bevacizumab, Carcinoma, Hepatocellular, Liver Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background and Aim Atezolizumab plus bevacizumab is used as a first‐line treatment for unresectable hepatocellular carcinoma (uHCC). However, the relationship between its adverse events (AEs) and treatment efficacy remains unclear. In this study, we aimed to clarify this association.
Methods
This study included 187 patients with uHCC treated with atezolizumab plus bevacizumab as first‐line therapy at 19 affiliated hospitals in the Osaka Liver Forum. A landmark analysis was conducted to address biases in AE incidence.
Results
The objective response and disease control rates were 28.2% and 69.6%, respectively. The median progression‐free survival (PFS) and overall survival (OS) were 7.4 and 24.6 months, respectively. Among the 187 patients, 178 (95.2%) experienced at least one AE, with proteinuria being the most common (41.7%), followed by hypertension (34.8%) and fatigue (30.5%). All three major AEs had a median onset time of 6 weeks. We set the landmark point at Week 9 after treatment initiation, considering that the onset time for most AEs was within 9 weeks. In the landmark analysis, multivariable analysis identified the absence of bevacizumab interruption within 9 weeks and the occurrence of hypertension within 9 weeks as predictors of prolonged PFS. mALBI Grade 1/2a, the occurrence of hypertension, and the absence of fatigue and rash within 9 weeks were associated with prolonged OS. These results were consistent with those from the 6‐week landmark analysis.
Conclusions
Patients with hypertension occurring as an AE within 9 weeks are expected to have better PFS and OS with atezolizumab plus bevacizumab therapy for uHCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine, Osaka, Japan.
- Department of Gastroenterology and Hepatology, Toyonaka Municipal Hospital, Toyonaka, Osaka, Japan.
- Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Osaka, Japan.
- Department of Gastroenterology and Hepatology, Osaka International Medical & Science Center, Osaka Keisatsu Hospital, Osaka, Osaka, Japan.
- Department of Gastroenterology and Hepatology, Ikeda Municipal Hospital, Ikeda, Osaka, Japan.
- Department of Gastroenterology and Hepatology, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan.
ORCID-Profile: Kazuki Maesaka, Hayato Hikita, Yuki Tahata, Takahiro Kodama, Ryotaro Sakamori, Tetsuo Takehara
Zitieren
APA
Maesaka, K., Hikita, H., Kai, M., Tahata, Y., Shirai, K., Doi, A., Murai, K., Saito, Y., Yamada, R., Kodama, T., Ohkawa, K., Miyazaki, M., Ishida, H., Matsumoto, K., Nozaki, Y., Yakushijin, T., Sakamori, R., Tatsumi, N., Iio, S., …, & Takehara, T. (2025). Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma. Journal of Gastroenterology and Hepatology, 40(10), 2580-2590. https://doi.org/10.1111/jgh.70068
Vancouver
Maesaka K, Hikita H, Kai M, Tahata Y, Shirai K, Doi A, et al. Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma. Journal of Gastroenterology and Hepatology. 2025;40(10):2580-2590. doi:10.1111/jgh.70068
BibTeX
@article{Maesaka2025,
author = {Maesaka, Kazuki and Hikita, Hayato and Kai, Machiko and Tahata, Yuki and Shirai, Kumiko and Doi, Akira and Murai, Kazuhiro and Saito, Yoshinobu and Yamada, Ryoko and Kodama, Takahiro and Ohkawa, Kazuyoshi and Miyazaki, Masanori and Ishida, Hisashi and Matsumoto, Kengo and Nozaki, Yasutoshi and Yakushijin, Takayuki and Sakamori, Ryotaro and Tatsumi, Nobuyuki and Iio, Sadaharu and Nawa, Takatoshi and Kakita, Naruyasu and Nakahara, Masanori and Hosui, Atsushi and Usui, Takeo and Imanaka, Kazuho and Doi, Yoshinori and Sakakibara, Mitsuru and Yoshida, Yuichi and Tatsumi, Tomohide and Takehara, Tetsuo},
title = {Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma},
journal = {Journal of Gastroenterology and Hepatology},
year = {2025},
volume = {40},
number = {10},
pages = {2580--2590},
doi = {10.1111/jgh.70068}
}
EUVIMED